ARCHIVES

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 10 | October 26, 2001

Download PDF Visit The Full Archive

Related Articles

Outside Experts Might Lengthen NDA Approval, Peck Asserts

September 7, 1990

Komen Foundation Announces Second Grant Cycle For 1995

April 28, 1995

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

December 26, 2014

In Brief: Weicker Heads New Group For More Spending On Medical Research; Committee Oks Sullivan

March 3, 1989

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

July 27, 2001

Core Grant Guideline Revisions, Comprehensive Center Characteristics Changes Still Coming Up

July 13, 1979